KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Debt (2016 - 2025)

Gsk (GSK) has 7 years of Non-Current Debt data on record, last reported at $18.7 billion in Q4 2024.

  • For Q4 2024, Non-Current Debt fell 0.7% year-over-year to $18.7 billion; the TTM value through Dec 2024 reached $18.7 billion, down 0.7%, while the annual FY2024 figure was $18.7 billion, 1.32% down from the prior year.
  • Non-Current Debt reached $18.7 billion in Q4 2024 per GSK's latest filing, down from $18.9 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $18.9 billion in Q4 2023 and bottomed at $6.9 billion in Q4 2021.
  • Average Non-Current Debt over 3 years is $14.8 billion, with a median of $18.7 billion recorded in 2024.
  • The widest YoY moves for Non-Current Debt: up 0.7% in 2024, down 0.7% in 2024.
  • A 3-year view of Non-Current Debt shows it stood at $6.9 billion in 2021, then soared by 173.54% to $18.9 billion in 2023, then decreased by 0.7% to $18.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $18.7 billion in Q4 2024, $18.9 billion in Q4 2023, and $6.9 billion in Q4 2021.